Product Description
Mechanisms of Action: NK1 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Generalized anxiety disorder|Phobia, Social|Insomnia|Parasomnias|Other|Deafness|Anesthesia Related|Hearing Loss|Tinnitus|Depressive Disorder
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2011-005216-28 | P2 |
Terminated |
Unknown |
2012-08-22 |
|
| VNK115640 | P2 |
Completed |
Other |
2012-08-01 |
|
| VNK114995 | P1 |
Completed |
Healthy Volunteers |
2011-10-01 |
|
| 2008-006345-72 | P2 |
Completed |
Insomnia |
2009-09-21 |